Primary hepatic lymphoma: A retrospective, multicenter rare cancer network study

Gamze Ugurluer, Robert C. Miller, Yexiong Li, Juliette Thariat, Pirus Ghadjar, Ulrike Schick, Mahmut Ozsahin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23- 86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1% of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9%). Most of the patients received Chop-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens; 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59%, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70%, respectively. Multivariate analysis revealed that fever, weight loss, and normal hemoglobin level were the independent factors influencing the outcome. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors.

Original languageEnglish (US)
Article number6502
Pages (from-to)118-123
Number of pages6
JournalRare Tumors
Volume8
Issue number3
DOIs
StatePublished - 2016

Fingerprint

Lymphoma
Liver
Neoplasms
Weight Loss
Fever
Survival Rate
Lymphoma, Large B-Cell, Diffuse
Sweat
Liver Function Tests
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Abdominal Pain
Multicenter Studies
Hemoglobins
Radiotherapy
Multivariate Analysis
Prospective Studies
Guidelines

Keywords

  • Chemotherapy
  • Non-Hodgkin’s lymphoma
  • Primary hepatic lymphoma

ASJC Scopus subject areas

  • Histology
  • Oncology

Cite this

Ugurluer, G., Miller, R. C., Li, Y., Thariat, J., Ghadjar, P., Schick, U., & Ozsahin, M. (2016). Primary hepatic lymphoma: A retrospective, multicenter rare cancer network study. Rare Tumors, 8(3), 118-123. [6502]. https://doi.org/10.4081/rt.2016.6502

Primary hepatic lymphoma : A retrospective, multicenter rare cancer network study. / Ugurluer, Gamze; Miller, Robert C.; Li, Yexiong; Thariat, Juliette; Ghadjar, Pirus; Schick, Ulrike; Ozsahin, Mahmut.

In: Rare Tumors, Vol. 8, No. 3, 6502, 2016, p. 118-123.

Research output: Contribution to journalArticle

Ugurluer, G, Miller, RC, Li, Y, Thariat, J, Ghadjar, P, Schick, U & Ozsahin, M 2016, 'Primary hepatic lymphoma: A retrospective, multicenter rare cancer network study', Rare Tumors, vol. 8, no. 3, 6502, pp. 118-123. https://doi.org/10.4081/rt.2016.6502
Ugurluer G, Miller RC, Li Y, Thariat J, Ghadjar P, Schick U et al. Primary hepatic lymphoma: A retrospective, multicenter rare cancer network study. Rare Tumors. 2016;8(3):118-123. 6502. https://doi.org/10.4081/rt.2016.6502
Ugurluer, Gamze ; Miller, Robert C. ; Li, Yexiong ; Thariat, Juliette ; Ghadjar, Pirus ; Schick, Ulrike ; Ozsahin, Mahmut. / Primary hepatic lymphoma : A retrospective, multicenter rare cancer network study. In: Rare Tumors. 2016 ; Vol. 8, No. 3. pp. 118-123.
@article{fbd07d976e264f55aac76d305dbb4b13,
title = "Primary hepatic lymphoma: A retrospective, multicenter rare cancer network study",
abstract = "Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23- 86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5{\%} of patients had fever, 17.1{\%} weight loss, and 9.8{\%} night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1{\%} of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9{\%}). Most of the patients received Chop-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens; 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59{\%}, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70{\%}, respectively. Multivariate analysis revealed that fever, weight loss, and normal hemoglobin level were the independent factors influencing the outcome. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors.",
keywords = "Chemotherapy, Non-Hodgkin’s lymphoma, Primary hepatic lymphoma",
author = "Gamze Ugurluer and Miller, {Robert C.} and Yexiong Li and Juliette Thariat and Pirus Ghadjar and Ulrike Schick and Mahmut Ozsahin",
year = "2016",
doi = "10.4081/rt.2016.6502",
language = "English (US)",
volume = "8",
pages = "118--123",
journal = "Rare Tumors",
issn = "2036-3605",
publisher = "PagePress",
number = "3",

}

TY - JOUR

T1 - Primary hepatic lymphoma

T2 - A retrospective, multicenter rare cancer network study

AU - Ugurluer, Gamze

AU - Miller, Robert C.

AU - Li, Yexiong

AU - Thariat, Juliette

AU - Ghadjar, Pirus

AU - Schick, Ulrike

AU - Ozsahin, Mahmut

PY - 2016

Y1 - 2016

N2 - Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23- 86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1% of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9%). Most of the patients received Chop-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens; 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59%, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70%, respectively. Multivariate analysis revealed that fever, weight loss, and normal hemoglobin level were the independent factors influencing the outcome. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors.

AB - Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23- 86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1% of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9%). Most of the patients received Chop-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens; 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59%, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70%, respectively. Multivariate analysis revealed that fever, weight loss, and normal hemoglobin level were the independent factors influencing the outcome. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors.

KW - Chemotherapy

KW - Non-Hodgkin’s lymphoma

KW - Primary hepatic lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84991434530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991434530&partnerID=8YFLogxK

U2 - 10.4081/rt.2016.6502

DO - 10.4081/rt.2016.6502

M3 - Article

AN - SCOPUS:84991434530

VL - 8

SP - 118

EP - 123

JO - Rare Tumors

JF - Rare Tumors

SN - 2036-3605

IS - 3

M1 - 6502

ER -